Clinical Outcome of Rifabutin-based Treatment for Pulmonary Tuberculosis in Solid Organ Transplant Recipients
Abstract
Abstract Backgrounds Rifabutin is often used instead of rifampin to treat tuberculosis (TB) in solid organ transplant recipients (SOTRs) due to fewer drug interactions with immunosuppressants. However, data on its efficacy are limited. Methods A retrospective, case-control study was conducted at a tertiary care center in Korea. SOTRs aged ≥18 years with culture-positive pulmonary TB treated with isoniazid and rifabutin for >80% of the treatment duration were included. Those with rifampin-resistant TB or who discontinued immunosuppressants prior to TB diagnosis were excluded. Each SOTR was matched to three non-SOTR controls treated with rifampin-based regimens. The primary outcome was treatment completion without early relapse. Logistic regression with and without overlap weighting was used for analysis. Results Forty SOTRs and 120 non-SOTRs were analyzed. Baseline TB severity markers (cavitary lesions, smear/culture-positivity) were comparable, but extrapulmonary TB and isoniazid resistance were more common in SOTRs. Treatment duration was longer in SOTRs (median 272 vs 187 days, P < .001). The primary outcome occurred in 90% of SOTRs and 96.7% of controls (P = .108). Treatment completion was lower in SOTRs (92.5% vs 100%, P = .015). No significant differences were observed in TB recurrence or 1-year mortality. TB-attributable deaths were absent in both groups. After overlap weighting, no significant difference was found in the primary outcome (aOR 0.36; 95% confidence…
How strong is the evidence?
Evidence Hub reads this as a case-control. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.
Read the paper
Related studies
- Antioxidant efficacy and the upregulation of Nrf2-mediated HO-1 expression by (+)-lariciresinol, a lignan isolated from Rubia philippinensis, through the activation of p38
- Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens
- Therapeutic Potential of Mesenchymal Stem Cells (MSCs) and MSC-Derived Extracellular Vesicles for the Treatment of Spinal Cord Injury
- The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model
- Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer
- In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.